Day: May 13, 2025

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Written by Customer Service on May 13, 2025. Posted in Public Companies.

Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT 2025) 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA. The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya’s core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated...

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Written by Customer Service on May 13, 2025. Posted in Public Companies.

SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company’s proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks a significant milestone in expanding Oragenics’ clinical development efforts internationally. With this clearance, Oragenics can initiate clinical trials in Australia and could begin patient enrollment as early as the second quarter of 2025. Once the Company is prepared to commence enrollment, patient enrollment and treatment administration...

BIGG, Netcoins make Strategic Investment in APX Lending

Written by Customer Service on May 13, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, Blockchain Intelligence Group, and TerraZero is pleased to announce a strategic investment in APX Lending by BIGG Digital Assets and the formation of a partnership between APX Lending and Netcoins.HighlightsBIGG Digital Assets has strategically invested in APX Lending’s latest fundraising round. APX Lending will use the funds for further aggressive growth in Canada and the US. Last month, APX Lending received Exemptive Relief from the Canadian Securities Administrators (CSA) – a first-of-its-kind decision for a crypto-backed lending business in Canada. Netcoins and APX Lending have entered into a partnership...

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.  The Company delivered a strong quarter of growth in revenue compared to the previous quarter, supported by ongoing expansion across safety-critical industries and steady customer...

Advanced Technology International Acquires Carrot

Written by Customer Service on May 13, 2025. Posted in Mergers And Acquisitions.

SUMMERVILLE, S.C., May 13, 2025 (GLOBE NEWSWIRE) — We are excited to announce that effective March 31, 2025, Advanced Technology International (ATI), a South Carolina based 501(c)3 public service nonprofit, acquired the assets of The Common Pool, LLC, dba Carrot. ATI is the Nation’s original and largest Consortium Management Firm supporting the U.S. Government by developing and managing a diverse range of research and development collaborations for the US Army, US Navy, Department of Health and Human Services, and the Department of Energy. Carrot is exclusively focused on designing, developing, and managing online contests and open-innovation initiatives. With this acquisition, ATI is now positioned to utilize new programs that incorporate Carrot’s use of incentives and rewards systems to facilitate competition and collaboration...

Apollo Hybrid Funds to Acquire PowerGrid Services from The Sterling Group

Written by Customer Service on May 13, 2025. Posted in Mergers And Acquisitions.

Investment Will Support Leading Provider of Electric Utility Maintenance and Construction Services in its Mission to Address Growing US Power Demand and Needed Grid Improvements HARTSELLE, Ala. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE:APO) today announced that Apollo-managed funds and affiliates associated with its hybrid strategies (the “Apollo Funds”) have agreed to acquire a majority stake in PowerGrid Services (“PGS”), a leading provider of maintenance and construction services to electric utilities across the United States. The Apollo Funds will partner with existing PGS investors, including company management and The Sterling Group, to support PGS’s continued growth. PowerGrid Services keeps the lights on across America by delivering essential utility services—from routine construction and maintenance to...

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

– Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M –– Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M –– New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 –– Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC – IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease, a rare genetic disorder that causes toxic copper buildup in organs like the liver and brain. Pooled results from three clinical trials (n=255)...

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Several Key Clinical Readouts in Addition to New Study Initiations Expected in 2025 SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025. Business Highlights:ART26.12:The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for the second quarter of 2025. Newly published peer-reviewed data revealed ART26.12’s potential in psoriasis, expanding...

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the first quarter ended March 31, 2025. “We’re off to a strong start across our pipeline...

Day: May 13, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals